theory clinical_79_1
imports Main

begin

typedecl entity
typedecl event

consts
  Patient :: "entity ⇒ bool"
  TNBC :: "entity ⇒ bool"
  Immunotherapy :: "entity ⇒ bool"
  PARPInhibitors :: "entity ⇒ bool"
  Appropriate :: "entity ⇒ entity ⇒ bool"
  SecondLineTherapy :: "entity ⇒ bool"
  Combination :: "entity ⇒ bool"
  Vemurafenib :: "entity ⇒ bool"
  MEKInhibitor :: "entity ⇒ bool"
  Unavailable :: "entity ⇒ entity ⇒ bool"
  Carboplatin :: "entity ⇒ bool"
  Paclitaxel :: "entity ⇒ bool"
  Activity :: "entity ⇒ bool"
  AdvancedMelanoma :: "entity ⇒ bool"
  BRAFV600 :: "entity ⇒ bool"
  Tolerated :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Demonstrates :: "event ⇒ bool"
  PredominantlyIn :: "entity ⇒ entity ⇒ bool"
  IrrespectiveOf :: "entity ⇒ bool"
  Treatment :: "entity ⇒ bool"
  BRAF :: "entity ⇒ bool"
  MEKInhibitors :: "entity ⇒ bool"
  Chemotherapy :: "entity ⇒ bool"
  Outcomes :: "entity ⇒ bool"
  Benefit :: "event ⇒ bool"
  Improve :: "event ⇒ bool"

(* Explanation 1: Patient with TNBC is not appropriate for immunotherapy or PARP inhibitors as second line therapy *)
axiomatization where
  explanation_1: "∃x y z. Patient x ∧ TNBC x ∧ Immunotherapy y ∧ PARPInhibitors z ∧ ¬Appropriate x y ∧ ¬Appropriate x z ∧ SecondLineTherapy x"

(* Explanation 2: Combination vemurafenib and MEK inhibitor is unavailable for the patient *)
axiomatization where
  explanation_2: "∃x y z. Combination x ∧ Vemurafenib x ∧ MEKInhibitor x ∧ Patient y ∧ Unavailable x y"

(* Explanation 3: The combination of vemurafenib, carboplatin, and paclitaxel is well tolerated and demonstrates encouraging activity, predominantly in patients with advanced melanoma and BRAFV600 mutations irrespective of prior treatment with BRAF and/or MEK inhibitors *)
axiomatization where
  explanation_3: "∃x y z w e1 e2. Combination x ∧ Vemurafenib x ∧ Carboplatin x ∧ Paclitaxel x ∧ Activity y ∧ Patient z ∧ AdvancedMelanoma z ∧ BRAFV600 z ∧ Tolerated e1 ∧ Agent e1 x ∧ Demonstrates e2 ∧ Agent e2 x ∧ PredominantlyIn y z ∧ IrrespectiveOf w ∧ Treatment w ∧ BRAF w ∧ MEKInhibitors w"

(* Explanation 4: Combination of vemurafenib with chemotherapy, such as carboplatin and paclitaxel, may benefit patients with advanced melanoma and BRAFV600 mutations by improving treatment outcomes *)
axiomatization where
  explanation_4: "∃x y z w e1 e2. Combination x ∧ Vemurafenib x ∧ Chemotherapy x ∧ Carboplatin x ∧ Paclitaxel x ∧ Patient y ∧ AdvancedMelanoma y ∧ BRAFV600 y ∧ Outcomes z ∧ Treatment z ∧ Benefit e1 ∧ Agent e1 x ∧ Improve e2 ∧ Agent e2 x ∧ Patient y"

theorem hypothesis:
  assumes asm: "Combination y ∧ Vemurafenib y ∧ Chemotherapy y"
  (* Hypothesis: Patient may benefit from combination vemurafenib and chemotherapy *)
  shows "∃x y e. Patient x ∧ Combination y ∧ Vemurafenib y ∧ Chemotherapy y ∧ Benefit e ∧ Agent e x ∧ Source e y"
proof -
  (* From the assumption, we have the known information about the combination, vemurafenib, and chemotherapy. *)
  from asm have "Combination y ∧ Vemurafenib y ∧ Chemotherapy y" by meson
  (* Explanation 4 states that the combination of vemurafenib with chemotherapy, such as carboplatin and paclitaxel, may benefit patients with advanced melanoma and BRAFV600 mutations by improving treatment outcomes. *)
  (* This implies that there exists a patient who may benefit from this combination. *)
  from explanation_4 have "∃x e. Patient x ∧ Benefit e ∧ Agent e y" sledgehammer
  (* Therefore, we can conclude that there exists a patient who may benefit from the combination of vemurafenib and chemotherapy. *)
  then show ?thesis <ATP>
qed

end
